Page 165 - E-book การประชุมวิชาการครั้งที่ 36

4. สตรีที่ได้รับการฉีดวัคซีนครบแล้ว ยังคงต้องรับการตรวจคัดกรองมะเร็งปากมดลูก
ตามคำแนะนำของการตรวจคัดกรองเช่นเดียวกับสตรีทั่วไป

เอกสารอ้างอิง
1. Cox JT, Mayeaux EJ. The biology and importance of human papillomavirus infection.

nd
In: Mayeaux EJ, Cox JT, editors. Modern Colposcopy. 2 ed. Philadelphia: Lippincott Williams &
Wilkins; 2012. p. 73-101.
2. Huh WK. Human papillomavirus infection: a concise review of natural history. Obstet

Gynecol 2009;114:139-43.

3. Erickson BK, Einstein MH, Huh WK. Preinvasive disease of lower genital tract. In: Chi DS,
th
Berchuk A, Dizon DS, Yashar CM, editors. Principles and practice of gynecologic oncology. 7 ed.
Philadelphia: Wolters Kluwers; 2017. p. 321-58.

4. Massad LS. Preinvasive disease of the cervix. In: Di Saia PJ, Creasman WT, Mannel RS,
th
McMeekin DS, Mutch DG, editors. Clinical gynecologic oncology . 9 ed. Philadelphia: Elsevier;
2018. p. 1-19.

5. de Pokomandy A, Mayrand MH. HPV infection epidemiology and prevention. In: Ali
Ayhan, Nicholas Reed, Murat Gultekin, Polat Dursun, editors. Textbook in Gynaecological Oncology.

rd
3 ed. ESGO eAcademy 2016. p. 195-200.
6. Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. Final efficacy,
immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women

aged 16-26 years: a randomised, double-blind trial. Lancet 2017;390:2143-59.

7. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a
prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human

papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind,

randomised controlled trial. Lancet 2007;369:2161-70.
8. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic

quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young

women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet
Oncol 2005;6:271-8.

CPG: Primary Prevention of Cervical Cancer 149